496 related articles for article (PubMed ID: 32003247)
1. Efficacy of biologics in atopic dermatitis.
Wu J; Guttman-Yassky E
Expert Opin Biol Ther; 2020 May; 20(5):525-538. PubMed ID: 32003247
[No Abstract] [Full Text] [Related]
2. Current and emerging biologic and small molecule therapies for atopic dermatitis.
Li R; Hadi S; Guttman-Yassky E
Expert Opin Biol Ther; 2019 Apr; 19(4):367-380. PubMed ID: 30672355
[TBL] [Abstract][Full Text] [Related]
3. Biologics for Atopic Dermatitis.
Boguniewicz M
Immunol Allergy Clin North Am; 2020 Nov; 40(4):593-607. PubMed ID: 33012322
[TBL] [Abstract][Full Text] [Related]
4. Current and emerging biologics for the treatment of pediatric atopic dermatitis.
Ghamrawi R; Bell KA; Balogh EA; Strowd LC; Feldman SR
Expert Opin Biol Ther; 2020 Dec; 20(12):1435-1445. PubMed ID: 33078990
[TBL] [Abstract][Full Text] [Related]
5. Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab.
Brunner PM; Pavel AB; Khattri S; Leonard A; Malik K; Rose S; Jim On S; Vekaria AS; Traidl-Hoffmann C; Singer GK; Baum D; Gilleaudeau P; Sullivan-Whalen M; Fuentes-Duculan J; Li X; Zheng X; Estrada Y; Garcet S; Wen HC; Gonzalez J; Coats I; Cueto I; Neumann AU; Lebwohl MG; Krueger JG; Guttman-Yassky E
J Allergy Clin Immunol; 2019 Jan; 143(1):142-154. PubMed ID: 30121291
[TBL] [Abstract][Full Text] [Related]
6. A mathematical model to identify optimal combinations of drug targets for dupilumab poor responders in atopic dermatitis.
Miyano T; Irvine AD; Tanaka RJ
Allergy; 2022 Feb; 77(2):582-594. PubMed ID: 33894014
[TBL] [Abstract][Full Text] [Related]
7. Are Biologics Efficacious in Atopic Dermatitis? A Systematic Review and Meta-Analysis.
Snast I; Reiter O; Hodak E; Friedland R; Mimouni D; Leshem YA
Am J Clin Dermatol; 2018 Apr; 19(2):145-165. PubMed ID: 29098604
[TBL] [Abstract][Full Text] [Related]
8. Understanding the immune landscape in atopic dermatitis: The era of biologics and emerging therapeutic approaches.
Moyle M; Cevikbas F; Harden JL; Guttman-Yassky E
Exp Dermatol; 2019 Jul; 28(7):756-768. PubMed ID: 30825336
[TBL] [Abstract][Full Text] [Related]
9. The IL-4, IL-13 and IL-31 pathways in atopic dermatitis.
Dubin C; Del Duca E; Guttman-Yassky E
Expert Rev Clin Immunol; 2021 Aug; 17(8):835-852. PubMed ID: 34106037
[No Abstract] [Full Text] [Related]
10. What's New in Atopic Dermatitis.
Renert-Yuval Y; Guttman-Yassky E
Dermatol Clin; 2019 Apr; 37(2):205-213. PubMed ID: 30850043
[TBL] [Abstract][Full Text] [Related]
11. Dupilumab: A review of its use in the treatment of atopic dermatitis.
Gooderham MJ; Hong HC; Eshtiaghi P; Papp KA
J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S28-S36. PubMed ID: 29471919
[TBL] [Abstract][Full Text] [Related]
12. Biologics for Treatment of Atopic Dermatitis: Current Status and Future Prospect.
Ratchataswan T; Banzon TM; Thyssen JP; Weidinger S; Guttman-Yassky E; Phipatanakul W
J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1053-1065. PubMed ID: 33685604
[TBL] [Abstract][Full Text] [Related]
13. Atopic Dermatitis Host and Environment Model: Revisiting Therapeutic Options.
Lopes A; Sokolova A; Abreu C; Lopes C
Eur Ann Allergy Clin Immunol; 2020 Jan; 52(1):4-14. PubMed ID: 31789489
[TBL] [Abstract][Full Text] [Related]
14. Dupilumab for the treatment of atopic dermatitis: A clinical trial review.
McGregor S; Farhangian ME; Feldman SR
Expert Opin Biol Ther; 2015; 15(11):1657-60. PubMed ID: 26428945
[TBL] [Abstract][Full Text] [Related]
15. Atopic dermatitis in African American patients is T
Sanyal RD; Pavel AB; Glickman J; Chan TC; Zheng X; Zhang N; Cueto I; Peng X; Estrada Y; Fuentes-Duculan J; Alexis AF; Krueger JG; Guttman-Yassky E
Ann Allergy Asthma Immunol; 2019 Jan; 122(1):99-110.e6. PubMed ID: 30223113
[TBL] [Abstract][Full Text] [Related]
16. Biological Therapies for Atopic Dermatitis: A Systematic Review.
Zhou S; Qi F; Gong Y; Zhang J; Zhu B
Dermatology; 2021; 237(4):542-552. PubMed ID: 33735876
[TBL] [Abstract][Full Text] [Related]
17. The evolving landscape of biologic therapies for atopic dermatitis: Present and future perspective.
David E; Ungar B; Renert-Yuval Y; Facheris P; Del Duca E; Guttman-Yassky E
Clin Exp Allergy; 2023 Feb; 53(2):156-172. PubMed ID: 36653940
[TBL] [Abstract][Full Text] [Related]
18. Novel Therapeutic Approaches and Targets for the Treatment of Atopic Dermatitis.
Pescitelli L; Rosi E; Ricceri F; Pimpinelli N; Prignano F
Curr Pharm Biotechnol; 2021; 22(1):73-84. PubMed ID: 32525769
[TBL] [Abstract][Full Text] [Related]
19. Dupilumab for Moderate-to-Severe Atopic Dermatitis.
Vangipuram R; Tyring SK
Skin Therapy Lett; 2017 Nov; 22(6):1-4. PubMed ID: 29091379
[TBL] [Abstract][Full Text] [Related]
20. Severe atopic dermatitis is characterized by selective expansion of circulating TH2/TC2 and TH22/TC22, but not TH17/TC17, cells within the skin-homing T-cell population.
Czarnowicki T; Gonzalez J; Shemer A; Malajian D; Xu H; Zheng X; Khattri S; Gilleaudeau P; Sullivan-Whalen M; Suárez-Fariñas M; Krueger JG; Guttman-Yassky E
J Allergy Clin Immunol; 2015 Jul; 136(1):104-115.e7. PubMed ID: 25748064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
